1312 GMT [Dow Jones] Hopes are rising for an FDA
approval of Sanofi-Aventis's (SNY) Acomplia without a panel meeting,
says Morgan Stanley. Sanofi-Aventis needs to be invited 60 days
prior to any panel and Endocrine and Metabolic Drug Advisory Panel
is scheduled for 12, 13 and 14 December, notes the bank. Absence
of an invitation could translate into further positive momentum
as the stock continues to play valuation catch up, says bank. It
rates Sanofi overweight with an EUR80 price target. Shares +0.4%
at EUR70.15 (LAF)
Read the complete news story here:
http://www.newratings.com
